This is a routine executive reorganization with no financial shock. Monitor for the CFO search outcome and any associated disclosure; the CEO doubling as CFO is a temporary structure that may signal cost discipline or delayed hiring. The R&D-focused appointment of Miralles (who was already consulting on clinical/regulatory strategy) is a positive for pipeline execution but not a catalyst.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 19 $8.55entry
- T+1 · 6mo ago −8.30%α −9.34% · $7.84
- T+5 · 6mo ago −8.19%α −10.43% · $7.85
- T+20 · 5mo ago +16.26%α +15.27% · $9.94
- T+60 · 3mo ago +32.16%α +25.87% · $11.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Artiva Biotherapeutics announced a reorganization of its executive team: CFO Thad Huston is departing effective May 22, 2026 with a $135,000 severance; CEO Fred Aslan assumes the principal financial officer role; and Diego Miralles transitions from the Board to President and Head of R&D with a $600,000 salary and inducement equity grants of 232,500 options and 77,500 RSUs. The CFO departure without a named successor creates a temporary gap in financial leadership, though the CEO taking over the role suggests internal continuity.
Key Facts
- CFO Thad Huston agreed to separation effective May 22, 2026; no replacement named yet; receives ~$135,000 severance (3 months salary) plus COBRA.
- CEO Fred Aslan appointed as principal financial and accounting officer, adding to his CEO and board member roles.
- Diego Miralles resigned from the Board effective May 18, 2026 to become President and Head of R&D; receives $600,000 base salary, 45% target bonus, and inducement awards of 232,500 options + 77,500 RSUs.
- Board size reduced from 8 to 7 members following Miralles' departure.
- All separations stated as not resulting from any dispute or disagreement with the company.
Financial Impact
CFO severance of approximately $135,000 is immaterial relative to the company's $228M market cap; inducement equity grants represent potential dilution of roughly 0.3% of outstanding shares.
Risk Factors
- Lack of a permanent CFO may strain financial reporting bandwidth if the CEO is overextended.
- Inducement equity grants add modest dilution over the vesting period.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-229714 |
| Document: 0001193125-26-229714-index-headers.html | 0001193125-26-229714 |
| Document: 0001193125-26-229714-index.html | 0001193125-26-229714 |
| Document: 0001193125-26-229714.txt | 0001193125-26-229714 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers